Clinical Trial Update: Efficacy, Safety and Tolerability of Agomelatine Sublingual Tablets in the Treatment of Major Depressive Disorder (MDD) [Phase 3]

View source ↗

Summary

Phase 3 trial update on efficacy, safety and tolerability of agomelatine sublingual tablets for major depressive disorder (MDD) completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• Agomelatine (agomelatine)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Major Depressive Disorder | Phase 3 | Status: COMPLETED